May 26, 2021 / 03:00PM GMT
Daniel Gregory Brennan - UBS Investment Bank, Research Division - Senior Equity Research Analyst of Healthcare Life Sciences
Welcome. Dan Brennan here on day 3 of the UBS Global Healthcare Conference. Hopefully, it's been a great event for all of you joining on the webcast. Pleased to be joined here in the 11:00 hour with senior management of Catalent, which is a buy-rated stock here, has been one of our top picks -- actually, published as a top -- as our top pick today, global or a U.S.-oriented research note that was put out by our strategist.
Really pleased to be joined by 2 members of the management team. We have Tom Castellano. Tom, who was -- I got to know in his previous role as -- in Investor Relations and subsequent to that, migrating back into the company and now is recently appointed Chief Financial Officer. So really pleased to have Tom here to be speaking on Catalent's behalf; as well we have Paul Surdez, who's Head of Investor Relations. (Operator Instructions) I'll check it throughout the presentation here.
So maybe, Tom, listen, congratulations on being appointed the new
Catalent Inc at UBS Global Healthcare Virtual Conference Transcript
May 26, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers